Cummins Lue, MD
Rheumatology · Little Rock, ARNPI 1497790562
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,868 of the $75,974 with a category attached, or 67.0%. 25 manufacturers reported payments, led by AbbVie at 41.2% of the total. Reporting peaked in 2019 at $47,822 and has fallen 97.8% since, to $1,034 in 2025. Among rheumatology clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $277.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$31K
- Regeneron Healthcare Solutions, Inc.$28K
- Regeneron$5K
- GSK$4K
- Pfizer$2K
- Fresenius Kabi USA, LLC$2K
- plus $3K from 19 others
What the payments were for
- Consulting fees$8,64311%
- Speaking & faculty fees$50,86867%
- Travel & lodging$10,57114%
- Food & beverage$5,4037%
- Education$4901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 82 | $31,338 |
| Regeneron Healthcare Solutions, Inc. | 39 | $28,098 |
| Regeneron | 10 | $5,242 |
| GSK | 35 | $4,426 |
| Pfizer | 11 | $1,915 |
| Fresenius Kabi USA, LLC | 4 | $1,564 |
| Sanofi | 2 | $1,232 |
| Amgen(2 entities) | 30 | $530 |
| E.r. Squibb & Sons, L.L.C. | 18 | $309 |
| Johnson & Johnson(2 entities) | 5 | $253 |
| UCB, Inc. | 7 | $198 |
| Novartis | 10 | $197 |
| AstraZeneca | 2 | $131 |
| Genentech, Inc. | 2 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Lilly USA, LLC | 3 | $67 |
| Boehringer Ingelheim | 2 | $63 |
| Mallinckrodt Enterprises LLC | 4 | $57 |
| Neurelis, Inc. | 1 | $34 |
| Sobi, Inc | 1 | $27 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| TG Therapeutics, Inc. | 1 | $20 |
| Grifols USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$75,974 in reported general payments places this provider in the 95th percentile of 48 rheumatology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 97 | $915,261 |
| Enbrel SureclickEtanercept | 49 | $353,529 |
| RinvoqUpadacitinib | 11 | $161,632 |
| OtezlaApremilast | 22 | $107,226 |
| XeljanzTofacitinib Citrate | 15 | $74,953 |
| Xeljanz XrTofacitinib Citrate | 13 | $73,045 |
| ActemraTocilizumab | 13 | $57,648 |
| Hydroxychloroquine Sulfate | 279 | $12,134 |
| Leflunomide | 126 | $8,426 |
| MethotrexateMethotrexate Sodium | 264 | $6,158 |
| Mycophenolate Mofetil | 68 | $4,597 |
| Sulfasalazine | 142 | $2,598 |
| Prednisone | 237 | $1,148 |
| Celecoxib | 35 | $1,125 |
| Duloxetine Hcl | 59 | $796 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $31,338 | $161,63211 claims |
| AmgenOtezla | $530 | $107,22622 claims |
| PfizerXeljanz | $1,915 | $74,95315 claims |
| Genentech, Inc.Actemra | $100 | $57,64813 claims |
| Amneal Pharmaceuticals LLCMycophenolate Mofetil | $24 | $4,59768 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 rheumatology providers in Arkansas.
Other rheumatology in Little Rock
- Jasen ChiLittle Rock$30K
- Richard HoukLittle Rock$25K
- Columbus BrownLittle Rock$18K
- Renee Peterkin-MccalmanLittle Rock$16K
- Daniel GonzalezLittle Rock$12K
- Safwan SakrLittle Rock$11K
- Alina VoineaLittle Rock$8K
- Tamer AlsebaiLittle Rock$6K
- Mavi Rivera PavonLittle Rock$5K
- Rina GuptaLittle Rock$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.